No Data
No Data
No Data
UBS Group: Maintains a "buy" rating on Innocare (09969) with a target price raised to 8.6 Hong Kong dollars.
UBS Group believes that the research results of the second phase can support the third phase of the study.
InnoCare Pharma's Phase 2 Study of Plaque Psoriasis Drug Results Show Positive Results
InnoCare Announces Breakthrough Psoriasis Drug Results
Express News | InnoCare Pharma Ltd - Icp-488 Shows Excellent Efficacy and Safety in 12-Week Study
Express News | InnoCare Announces Phase II Study Results of Tyk2 Inhibitor Icp-488 Meet Primary Endpoint in Psoriasis Patients
Innocare (688428.SH): Innovative drug ICP-488 obtained positive clinical trial results in Phase II related studies in patients with moderate to severe plaque psoriasis.
GeLongHui October 9th | innocare (688428.SH) announced recently that its innovative drug ICP-488 has achieved positive clinical trial results in a Phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. ICP-488 is a potent and highly selective oral TYK2 (tyrosine kinase 2) allosteric inhibitor that blocks the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons by binding to the TYK2-JH2 domain, thus inhibiting the pathological processes of autoimmune and inflammatory diseases.
No Data
No Data